Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3CNS 3Gastrointestinal 2Breast 2Other neoplasm 1Head & Neck 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Acute Lung Injury 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × pirfenidone × Breast × Clear all
NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Harbin Medical University

Phase 1/2 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05704166 2025-08-08

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Fujian Medical University Union Hospital

Phase 2 Recruiting
214 enrolled
Breast

Breast Neoplasms, Acute Lung Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡